Synapse - Shanu Modi

Results (22)

Phosphorylation-driven epichaperome assembly is a regulator of cellular adaptability and proliferation

Journal Article

Roychowdhury, T.; McNutt, S. W.; Pasala, C.; Nguyen, H. T.; Thornton, D. T.; Sharma, S.; Botticelli, L.; Digwal, C. S.; Joshi, S.; Yang, N.; more...
Nature Communications (2024)

Fulltext@MSK | Save

Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation

Journal Article

Rodina, A.; Xu, C.; Digwal, C. S.; Joshi, S.; Patel, Y.; Santhaseela, A. R.; Bay, S.; Merugu, S.; Alam, A.; Yan, P.; more...
Nature Communications (2023)

Fulltext@MSK | Save

A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab

Journal Article

Adusumilli, P. S.; Zauderer, M. G.; Rivière, I.; Solomon, S. B.; Rusch, V. W.; O'Cearbhaill, R. E.; Zhu, A.; Cheema, W.; Chintala, N. K.; Halton, E.; more...
Cancer Discovery (2021)

Fulltext@MSK | Save

Measuring tumor epichaperome expression using [(124)I] PU-H71 positron emission tomography as a biomarker of response for PU-H71 plus nab-paclitaxel in HER2-negative metastatic breast cancer

Journal Article

Jhaveri, K. L.; dos Anjos, C. H.; Taldone, T.; Wang, R.; Comen, E.; Fornier, M.; Bromberg, J. F.; Ma, W.; Patil, S.; Rodina, A.; more...
JCO Precision Oncology (2020)

Fulltext@MSK | Save

First-in-human trial of epichaperome-targeted PET in patients with cancer

Journal Article

Dunphy, M. P. S.; Pressl, C.; Pillarsetty, N.; Grkovski, M.; Modi, S.; Jhaveri, K.; Norton, L.; Beattie, B. J.; Zanzonico, P. B.; Zatorska, D.; more...
Clinical Cancer Research (2020)

Fulltext@MSK | Save

Molecular stressors engender protein connectivity dysfunction through aberrant N-glycosylation of a chaperone

Journal Article

Yan, P.; Patel, H. J.; Sharma, S.; Corben, A.; Wang, T.; Panchal, P.; Yang, C.; Sun, W.; Araujo, T. L.; Rodina, A.; more...
Cell Reports (2020)

Fulltext@MSK | Save

Paradigms for precision medicine in epichaperome cancer therapy

Journal Article

Pillarsetty, N.; Jhaveri, K.; Taldone, T.; Caldas-Lopes, E.; Punzalan, B.; Joshi, S.; Bolaender, A.; Uddin, M. M.; Rodina, A.; Yan, P.; more...
Cancer Cell (2019)

Fulltext@MSK | Save

Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary efficacy in combination with anti-PD-1 agent

Meeting Abstract

Adusumilli, P. S.; Zauderer, M. G.; Rusch, V. W.; O'Cearbhaill, R.; Zhu, A.; Ngai, D.; McGee, E.; Chintala, N.; Messinger, J.; Cheema, W.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: Safety and efficacy

Meeting Abstract

Adusumilli, P. S.; Zauderer, M. G.; Rusch, V. W.; O'Cearbhaill, R. E.; Zhu, A.; Ngai, D. A.; McGee, E.; Chintala, N. K.; Messinger, J. C.; Vincent, A.; more...
Cancer Research (2019)

Fulltext@MSK | Save

Tumor epichaperome expression using (124)I PU-H71 PET (PU-PET) as a biomarker of response for PU-H71 plus nab-paclitaxel in HER2 negative (HER2-) metastatic breast cancer (MBC)

Meeting Abstract

Jhaveri, K.; Dunphy, M.; Wang, R.; Comen, E.; Fornier, M.; Moynahan, M. E.; Bromberg, J.; Ma, W.; Patil, S.; Taldone, T.; more...
Cancer Research (2019)

Fulltext@MSK | Save